对中度至重度亚托皮性皮炎的阿帕达西尼布:根据基线关键特征对三项随机阶段3试验的分层分析
J P Thyssen1, D Thaçi2, T Bieber3,4
1Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
概括
在不同患者群体中,upadacitinib有效治疗中度至重度的亚托皮炎 (AD),显示出高皮肤清除和的缓解. 这支持upadacitinib作为AD的多功能治疗选择.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托邦性皮肤炎 (AD) 是一种复杂的皮肤疾病,患者表型各异.
- 了解这些子组的治疗疗效对于个性化医学至关重要.
- 目前没有生物标志物能够预测AD患者对upadacitinib的反应.
研究的目的:
- 评估阿帕达西提尼布在中度至重度阿尔茨海默病患者中的疗效.
- 评估各种患者亚组的治疗反应,包括人口统计和疾病特征.
- 根据先前的治疗史分析疗效.
主要方法:
- 对第三阶段研究的特点分析 (Measure Up 1,Measure Up 2,AD Up).
- 随机对照试验涉及upadacitinib (每天15mg或30mg) 或安慰剂.
- 在AD Up研究中同时使用局部皮质类固醇.
主要成果:
- 与安慰剂相比,upadacitinib在实现显著的皮肤改善 (EASI-75) 和减少 (NRS 0/1) 中表现出更高的疗效.
- 在所有分析的子组中观察到一致的疗效:年龄,性别,种族,BMI,疾病严重程度和先前的治疗.
- 高比例的患者获得了验证的调查员全球评估 (IGA) 0或1.
结论:
- 在中度至重度的AD患者中,upadacitinib提供了一致且高的皮肤清除率和的缓解.
- 药物的有效性在各种患者群体中保持不变,无论基线特征如何.
- 乌帕达西提尼布是适度至重度亚托邦性皮肤炎的广泛患者的耐受性良好和有效的治疗选择.
相关概念视频
01:11Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
01:16Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K